Neurotherapeutics

metrics 2024

Connecting Researchers to the Frontiers of Neurotherapeutics.

Introduction

Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

Metrics 2024

SCIMAGO Journal Rank1.62
Journal Impact Factor5.60
Journal Impact Factor (5 years)6.90
H-Index136
Journal IF Without Self5.60
Eigen Factor0.01
Normal Eigen Factor2.20
Influence1.84
Immediacy Index1.30
Cited Half Life5.60
Citing Half Life7.70
JCI1.39
Total Documents1792
WOS Total Citations8591
SCIMAGO Total Citations27809
SCIMAGO SELF Citations215
Scopus Journal Rank1.62
Cites / Document (2 Years)5.13
Cites / Document (3 Years)5.64
Cites / Document (4 Years)6.02

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #14/272
Percentile 94.85
Quartile Q1
Neurology (clinical) in Medicine
Rank #32/400
Percentile 92.00
Quartile Q1
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #30/313
Percentile 90.42
Quartile Q1

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 28/277
Percentile 90.10
Quartile Q1
NEUROSCIENCES
Rank 41/310
Percentile 86.90
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 31/354
Percentile 91.40
Quartile Q1

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 33/278
Percentile 88.13
Quartile Q1
NEUROSCIENCES
Rank 43/310
Percentile 86.13
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 35/354
Percentile 90.11
Quartile Q1

Quartile History

Similar Journals

Neurological Sciences and Neurophysiology

Fostering innovation in neurological sciences.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2636-865XFrequency: 4 issues/year

Neurological Sciences and Neurophysiology, published by Wolters Kluwer Medknow Publications, serves as a pivotal platform for dissemination and discussion of recent advancements and research in the fields of neurology and neurophysiology. Since its transition to an Open Access format in 2020, this journal aims to enhance accessibility to crucial developments in neurological sciences for researchers, professionals, and students alike. With an ISSN of 2636-865X, it seeks to bridge the gap between clinical practice and experimental science, promoting innovative approaches to neurological disorders. While currently ranked in the Q4 quartile in the Neurology category, the journal is committed to improving its standing through rigorous peer review and publication of high-quality research. The journal's scope encompasses a wide range of topics, ensuring that it appeals to a diverse audience, while its Scopus ranks indicate its emerging presence in the global scientific community. Located in Mumbai, India, the journal welcomes contributions that push the boundaries of our understanding of the nervous system, making it a vital resource for scholars in this dynamic field.

NEUROLOGICAL RESEARCH

Connecting Researchers to the Heart of Neurology
Publisher: TAYLOR & FRANCIS LTDISSN: 0161-6412Frequency: 12 issues/year

NEUROLOGICAL RESEARCH, published by TAYLOR & FRANCIS LTD, is a distinguished journal focusing on the diverse and evolving field of neurology. Established in 1979, this journal has been a prominent platform for disseminating groundbreaking research and clinical advances up to 2024. With an ISSN of 0161-6412 and an E-ISSN of 1743-1328, it offers valuable insights for researchers, professionals, and students interested in the intricate workings of the nervous system. The journal holds a respectable Q2 ranking in the field of Medicine (miscellaneous) and Q3 in the categories of Neurology and Clinical Neurology, reflecting its commitment to high-quality research. Although NEUROLOGICAL RESEARCH does not currently offer an open access option, its contributions to the literature are vital for fostering advancements in neurological understanding and treatment. With an engaged readership and a mission to advance scientific knowledge, NEUROLOGICAL RESEARCH serves as a crucial resource for anyone dedicated to neurological health and innovation.

MOLECULAR NEUROBIOLOGY

Pioneering Discoveries in Molecular Mechanisms of the Brain
Publisher: SPRINGERISSN: 0893-7648Frequency: 12 issues/year

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Current Journal of Neurology

Advancing neurology through open dialogue.
Publisher: TEHRAN UNIV MEDICAL SCIENCESISSN: 2717-011XFrequency: 4 issues/year

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

Current Treatment Options in Neurology

Enhancing Patient Outcomes through Comprehensive Reviews
Publisher: CURRENT MEDICINE GROUPISSN: 1092-8480Frequency: 12 issues/year

Current Treatment Options in Neurology, published by CURRENT MEDICINE GROUP, is a pivotal journal in the field of clinical neurology, dedicated to enhancing the understanding and management of neurological disorders. With a print ISSN of 1092-8480 and an E-ISSN of 1534-3138, this journal serves as a vital resource for clinicians, researchers, and students alike, providing evidence-based insights and treatment strategies from its continuous publication since its inception in 1999. It currently holds a respectable rank in the Q3 quartile, reflecting its competitive standing in the Scopus rankings for clinical neurology, placing it at the 51st percentile. Although not classified as Open Access, the journal continues to provide valuable contributions that inform clinical practices and improve patient outcomes in neurological care. With its comprehensive reviews and clinical focus, Current Treatment Options in Neurology remains an essential platform for disseminating the latest advancements in treatment methodologies and therapeutic options, solidifying its importance in the ever-evolving landscape of neurology.

Current Molecular Pharmacology

Advancing the Frontiers of Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

NEUROMOLECULAR MEDICINE

Connecting Molecular Science with Neurological Health
Publisher: HUMANA PRESS INCISSN: 1535-1084Frequency: 4 issues/year

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Translational Neuroscience

Connecting Scholars and Practitioners for Impactful Discoveries.
Publisher: DE GRUYTER POLAND SP Z O OISSN: 2081-3856Frequency: 1 issue/year

Translational Neuroscience, published by DE GRUYTER POLAND SP Z O O, is a leading open-access journal since its inception in 2015, dedicated to the multidisciplinary exploration of neurological research and its clinical applications. With an ISSN of 2081-3856 and an E-ISSN of 2081-6936, the journal serves as a crucial platform for scholars and practitioners to disseminate innovative findings and theoretical advancements in the field of neuroscience. Covering various aspects of general neuroscience, it is ranked in the Q3 quartile for 2023 and positioned at Rank #75 out of 113 in its category, reflecting its growing impact within the scientific community. The journal strives to bridge the gap between laboratory research and clinical practice, fostering collaboration among researchers, clinicians, and educators. The editorial team is committed to maintaining high publication standards that engage the audience with rigorous research while promoting a culture of open science. For those interested in the forefront of neuroscience research, Translational Neuroscience offers an invaluable resource for knowledge and innovation.

Current Neuropharmacology

Unraveling the complexities of neuropharmacology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-159XFrequency: 8 issues/year

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Journal of Neuroimmune Pharmacology

Exploring the Intersection of Neuroscience and Pharmacology
Publisher: SPRINGERISSN: 1557-1890Frequency: 4 issues/year

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.